$1.91 Billion is the total value of NEA Management Company, LLC's 34 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Sell | TESARO INC | $520,542,000 | -8.0% | 8,854,255 | -10.1% | 27.18% | +6.3% |
| GRPN | GROUPON INC | $222,190,000 | -30.2% | 44,172,953 | 0.0% | 11.60% | -19.4% | |
| ARDX | Buy | ARDELYX INC | $164,397,000 | +123.4% | 10,294,096 | +83.1% | 8.58% | +158.0% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $129,748,000 | +0.8% | 7,641,250 | -28.3% | 6.78% | +16.3% |
| EPZM | EPIZYME INC | $123,594,000 | +27.8% | 5,149,740 | 0.0% | 6.45% | +47.6% | |
| OPWR | OPOWER INC | $103,559,000 | +13.6% | 8,997,290 | 0.0% | 5.41% | +31.2% | |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $100,174,000 | -40.8% | 1,139,890 | -50.0% | 5.23% | -31.6% |
| GLYC | GLYCOMIMETICS INC | $68,172,000 | -4.4% | 8,575,135 | 0.0% | 3.56% | +10.4% | |
| DERM | DERMIRA INC | $61,542,000 | +14.3% | 3,506,649 | 0.0% | 3.21% | +32.0% | |
| NVRO | Sell | NEVRO CORP | $53,397,000 | -18.7% | 993,428 | -27.5% | 2.79% | -6.1% |
| VTAE | VITAE PHARMACEUTICALS INC | $37,630,000 | +23.0% | 2,613,199 | 0.0% | 1.96% | +42.0% | |
| HIVE | Sell | AEROHIVE NETWORKS INC | $32,677,000 | +50.7% | 4,681,455 | -3.7% | 1.71% | +74.1% |
| LOXO | LOXO ONCOLOGY INC | $32,313,000 | +44.8% | 1,792,207 | 0.0% | 1.69% | +67.2% | |
| TRVN | TREVENA INC | $30,121,000 | -4.0% | 4,811,691 | 0.0% | 1.57% | +10.9% | |
| TCON | TRACON PHARMACEUTICALS INC | $21,410,000 | -19.3% | 1,889,652 | 0.0% | 1.12% | -6.8% | |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $21,107,000 | -49.0% | 3,945,191 | 0.0% | 1.10% | -41.1% | |
| CRCM | CARE COM INC | $19,305,000 | -21.9% | 3,260,989 | 0.0% | 1.01% | -9.8% | |
| LXRX | Sell | LEXICON PHARMACEUTICALS INC | $19,177,000 | +22.3% | 2,382,286 | -85.7% | 1.00% | +41.2% |
| OREX | OREXIGEN THERAPEUTICS INC | $18,360,000 | -36.8% | 3,709,000 | 0.0% | 0.96% | -27.0% | |
| ZSAN | ZOSANO PHARMA CORP | $15,649,000 | -28.3% | 2,158,543 | 0.0% | 0.82% | -17.2% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $14,025,000 | +22.9% | 4,659,333 | 0.0% | 0.73% | +41.9% | |
| MM | MILLENNIAL MEDIA INC | $13,324,000 | +11.7% | 8,224,752 | 0.0% | 0.70% | +29.1% | |
| TRGT | TARGACEPT INC | $12,741,000 | -6.1% | 4,566,666 | 0.0% | 0.66% | +8.5% | |
| ABIO | New | ARCA BIOPHARMA INC | $11,755,000 | – | 10,221,465 | +100.0% | 0.61% | – |
| ZHNE | ZHONE TECHNOLOGIES INC | $10,710,000 | +72.3% | 4,781,290 | 0.0% | 0.56% | +98.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $10,411,000 | -10.1% | 3,243,150 | 0.0% | 0.54% | +3.8% | |
| ROKA | ROKA BIOSCIENCE INC | $8,373,000 | -18.7% | 3,220,433 | 0.0% | 0.44% | -6.2% | |
| EXEL | EXELIXIS INC | $8,298,000 | +46.3% | 2,207,000 | 0.0% | 0.43% | +69.1% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $7,691,000 | -30.7% | 2,546,843 | 0.0% | 0.40% | -19.9% | |
| ECOM | CHANNELADVISOR CORP | $6,652,000 | +23.3% | 556,692 | 0.0% | 0.35% | +42.2% | |
| CVT | Sell | CVENT INC | $6,293,000 | -92.5% | 244,106 | -91.9% | 0.33% | -91.3% |
| PRTK | PARATEK PHARMACEUTICALS INC | $4,481,000 | -17.6% | 173,892 | 0.0% | 0.23% | -4.9% | |
| ARQL | ARQULE INC | $4,033,000 | -28.6% | 2,520,316 | 0.0% | 0.21% | -17.3% | |
| AGRX | AGILE THERAPEUTICS INC | $1,147,000 | -7.3% | 133,488 | 0.0% | 0.06% | +7.1% | |
| NURO | Exit | NEUROMETRIX INC | $0 | – | -57,273 | -100.0% | -0.00% | – |
| WIFI | Exit | BOINGO WIRELESS INC | $0 | – | -2,496,312 | -100.0% | -0.85% | – |
| HPTX | Exit | HYPERION THERAPEUTICS INC | $0 | – | -2,384,221 | -100.0% | -4.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-07-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.